Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

@article{Demidem1997ChimericA,
  title={Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.},
  author={A{\"i}cha Demidem and Thanh Thu Lam and Steve Alas and Kandasamy Hariharan and Nabil Hanna and Benjamin Bonavida},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={1997},
  volume={12 3},
  pages={177-86}
}
More than 50% of patients with aggressive B lymphomas and the majority of patients with low grade lymphomas are not cured by current therapeutic strategies. The lymphomas express the B cell antigen CD20 on the cell surface and this antigen serves as target for antibody-directed therapies. Clinical studies with encouraging results have been underway with the… CONTINUE READING